What are the common side effects of antidiabetic agents for each drug class?

Common Side Effects of Antidiabetic Agents by Drug Class

The side effect profiles of antidiabetic medications vary significantly by class, with metformin causing primarily gastrointestinal symptoms, sulfonylureas and insulin causing hypoglycemia and weight gain, SGLT2 inhibitors causing genitourinary infections and volume depletion, GLP-1 agonists causing nausea and GI disturbances, DPP-4 inhibitors being generally well-tolerated with rare pancreatitis, and thiazolidinediones causing fluid retention and heart failure risk. 1

Metformin (Biguanides)

Gastrointestinal Effects:

• Nausea, diarrhea, bloating, and abdominal discomfort are the most common side effects 2, 3
• These can be mitigated by gradual dose titration or using extended-release formulations 3

Metabolic Effects:

• Vitamin B12 deficiency with prolonged use, requiring periodic monitoring especially in patients with anemia or neuropathy 2, 1, 3
• Rare lactic acidosis (though very rare), primarily when eGFR <30 mL/min/1.73 m² or in settings of severe illness, dehydration, or acute kidney injury 2, 1

Cardiovascular:

• Chest discomfort and palpitations (uncommon) 2

Critical Pitfall: Metformin must be discontinued during acute illness with dehydration or hypoxemia, and when administering radiocontrast material 4, 1

Sulfonylureas (Second Generation)

Metabolic Effects:

• Hypoglycemia is the primary concern - significantly higher risk than most other oral agents 2, 1
• Weight gain (relatively modest in large cohorts) 1

Neurological:

• Dizziness and nervousness 2

Cardiovascular:

• May increase cardiovascular mortality (observational data) 2, 1
• Syncope 2

Important Note: Glyburide has higher hypoglycemia risk compared to glipizide, glimepiride, and gliclazide 1. Glyburide is not recommended in chronic kidney disease 2

Insulin

Metabolic:

• Hypoglycemia - highest risk among all antidiabetic agents 2, 1
• Weight gain 2

Cardiovascular:

• Fluid retention 2

Other:

• Increased serious adverse events compared to usual care 5

SGLT2 Inhibitors

Genitourinary:

• Genital mycotic infections (10-15% in women, higher in uncircumcised men and those with prior infections) - most common adverse effect 6, 1
• Urinary tract infections

Volume-Related:

• Acute kidney injury risk 6, 1
• Dehydration and orthostatic hypotension, especially when combined with diuretics and/or ACE inhibitors/ARBs 1
• Temporary eGFR reduction up to 15% (usually resolves in 1-3 months) 6

Metabolic:

• Diabetic ketoacidosis (incidence 0.1%), can occur with normal or modestly elevated glucose (<14 mmol/L) 6, 1
• Normal anion gap acidosis (rare) 6

Musculoskeletal (Canagliflozin-specific):

• Increased fracture risk (15.4 vs 11.9 per 1,000 patient-years; HR 1.26) 1
• Lower-limb amputation risk (6.3 vs 3.4 per 1,000 patient-years; HR 1.97) 1

Critical Management: Must be held during "sick days" with dehydrating illness 6

GLP-1 Receptor Agonists

Gastrointestinal:

• Nausea and diarrhea - most common, sometimes leading to treatment discontinuation 2, 1, 7
• Vomiting and abdominal discomfort

Hepatobiliary:

• Cholelithiasis 2

Cardiovascular:

• Increased heart rate 2

Endocrine:

• FDA Black Box Warning: Risk of thyroid C-cell tumors; contraindicated in patients with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 2

Other:

• Minimal hypoglycemia risk when used alone, but increases hypoglycemic potential when combined with insulin or sulfonylureas 1

DPP-4 Inhibitors

Generally Well-Tolerated:

• Weight neutral 1
• Minimal hypoglycemia as monotherapy, but 50% increased risk when added to sulfonylureas 1

Musculoskeletal:

• Joint pain 2
• Musculoskeletal side effects (rare) 1

Gastrointestinal:

• Acute pancreatitis (rare but reported) 2, 1

Cardiovascular:

• Saxagliptin specifically associated with increased heart failure hospitalization risk 2, 1
• Alogliptin also shows heart failure signal 1

Dermatological:

• Bullous pemphigoid (DPP-4 inhibitor-associated) 8

Thiazolidinediones (TZDs)

Cardiovascular:

• FDA Black Box Warning: May cause or exacerbate heart failure; not recommended in symptomatic heart failure 2, 1
• Fluid retention 2, 1

Metabolic:

• Weight gain 2, 1
• Increased LDL cholesterol (rosiglitazone) 2

Musculoskeletal:

• Bone fractures, particularly in postmenopausal women 2, 1, 7

Oncologic:

• Bladder cancer risk (pioglitazone) 2, 1, 7
• Fatal hepatic failure (troglitazone - no longer recommended) 4

Important Consideration: Lower-dose therapy (e.g., pioglitazone 15-30 mg) mitigates weight gain and edema 1

Alpha-Glucosidase Inhibitors

Gastrointestinal:

• Bloating, flatulence, diarrhea, and abdominal discomfort - dose-related and common 9
• These side effects limit their use despite low hypoglycemia risk

Hepatic:

• Hepatic injury with chronic therapy (acarbose) 10

Meglitinides

Metabolic:

• Hypoglycemia (repaglinide > nateglinide) 9
• Weight gain (less than sulfonylureas)

Practical Limitation:

• Frequent dosing requirements 9

---

Key Clinical Pearls:

• Hypoglycemia risk hierarchy: Insulin > Sulfonylureas > Meglitinides >> GLP-1 agonists/SGLT2 inhibitors/DPP-4 inhibitors/Metformin (minimal when used alone)

• Weight effects: Weight gain with insulin, sulfonylureas, TZDs; weight loss with GLP-1 agonists and SGLT2 inhibitors; weight neutral with metformin and DPP-4 inhibitors 1

• Heart failure considerations: Avoid TZDs and saxagliptin/alogliptin in heart failure; SGLT2 inhibitors are beneficial 2, 6, 1

• Renal adjustments required: Most agents except linagliptin need dose adjustment with declining kidney function 2, 1